Ozelle Showcases Scalable AI-Driven Hematology System O-Cyte 1 at MEDICA 2026

Ozelle Unveils O-Cyte 1: A Leap in Hematology

At the upcoming MEDICA 2026, Ozelle, a pioneering company in AI-driven healthcare solutions, will introduce the O-Cyte 1—an innovative hematology analyzer at the forefront of technology and design. This device reflects the shifting landscape in hematological diagnostics, where artificial intelligence plays a crucial role in cell morphology analysis.

The integration of AI in hematology has become indispensable. As routine diagnostics evolve, the demand for lab equipment has increased, pushing beyond simple automated cell classification. O-Cyte 1 combines Complete Blood Count (CBC) tests with detailed cell imaging to facilitate expert reviews by linking images to numerical results. This capability allows for a more thorough investigation into blood disorders, granting lab professionals vital visual support when needed.

One of the standout features of the O-Cyte 1 is its capacity for scalable throughput. Capable of conducting up to 60 tests per hour from a standalone unit, the device can be expanded through a cascade setup, reaching an impressive 360 tests in the same timeframe. This flexibility enables laboratories to manage workloads efficiently, scaling operations up or down based on real-time demand.

The design of the O-Cyte 1 is also centered around user ease and routine maintenance. It includes an integrated reagents kit and key components housed within consumable materials to streamline reagent handling and reduce the burden of regular upkeep. Moreover, integrated self-testing and interchangeable modules simplify error detection and maintenance, thereby minimizing downtime.

Ozelle’s introduction of the O-Cyte 1 comes alongside exciting advancements in digital morphology standards. At the recent general assembly of the International Council for Standardization in Hematology (ICSH), a project to standardize digital morphology was approved, emphasizing the importance of reproducibility and quality assurance in the field.

In addition to the O-Cyte 1, Ozelle will also showcase other groundbreaking systems such as the EHBT-75, which integrates 7-Diff hematology with cell imaging and morphology analysis, as well as the EHBT-50, a compact platform that combines hematology, immunoassay, and dry biochemistry techniques. Attendees will also have the chance to learn about 'Open Dx', Ozelle's AI Workbench for assisted report verification and result sharing, demonstrating the company's commitment to enhancing diagnostic accuracy and efficiency.

Visitors to MEDICA 2026, taking place from November 16 to 19 at Düsseldorf Messe, are invited to experience the O-Cyte 1 and discuss potential distribution partnerships at booth D63, Hall 1. With its innovative design and advanced technology, the O-Cyte 1 aligns with Ozelle’s vision to transform hematological analysis into a more reliable, verifiable, and scalable process in clinical settings.

Ozelle, founded in Silicon Valley in 2014, specializes in AI-driven hematology solutions and integrated diagnostic systems for both human and veterinary medicine. By merging cell imaging with intelligent analysis, the company strives to meet the everyday needs of clinical practice.

Visit Ozelle's website for more information and insights into their cutting-edge technologies.